

S/N 10/502,066

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	LAUTT	Examiner:	S. GEMBEH
Serial No.:	10/502,066	Group Art Unit:	1614
Filed:	OCTOBER 27, 2004	Docket No.:	14430.5USWO
Conf. No.:	8639	Customer No.:	23552
Title:	USE OF CHOLINESTERASE ANTAGONISTS TO TREAT INSULIN RESISTANCE		

INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(c))

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted after the mailing date of a first Office Action on-the-merits or a first Office Action after filing a Request for Continued Examination under 37 C.F.R. § 1.114 or a CPA under 37 C.F.R. § 1.53(d), but before the mailing date of: i) a final action under 37 C.F.R. § 1.113; ii) a Notice of Allowance under 37 C.F.R. § 1.311; or iii) an action that otherwise closes prosecution on the application. Please charge Deposit Account #13-2725 in the amount of \$180.00 under 37 C.F.R. § 1.17(p) for consideration of the items listed on the enclosed Form 1449.

A copy of any foreign patent document or "Other Document" listed on the Form 1449 is enclosed, in accordance with 37 C.F.R. § 1.98(a)(2). Because this application was filed after June 30, 2003, copies of the U.S. Patents and U.S. patent publications listed on the enclosed Form 1449 are not provided.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.


Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.

Respectfully submitted,

MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
612.332.5300

Date: July 13, 2007



Brian R. Dorn
Reg. No. 57,395
BDorn:jm

FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 14430.5USWO	Application Number: 10/502,066
	Applicant: Lautt	
	Filing Date: July 21, 2004	Group Art Unit: 1614

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	2003/0235609	12-25-2003	Lautt			
	2004/0209849	10-21-2004	Fischer			

FOREIGN PATENT DOCUMENTS							
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Office Action August 24, 2005 for U.S. Appl. No. 10/530,478
		Ponec et al., "Neostigmine for the treatment of acute colonic pseudo-obstruction," N. Engl. J. Med. 341: 137-141 (1999).
		www.medsafe.gov.nz/Profs/Datasheet/n/Neostigmineinj.htm (1996)
		Wang et al., "Evidence of nitric oxide, a flow-dependent factor, being a trigger of liver regeneration in rats," Can. J. Physiol. Pharmacol. 76:1072-1079 (1998)

23552

PATENT TRADEMARK OFFICE

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	